Biotron Limited ( (AU:BIT) ) just unveiled an update.
Biotron Limited has announced a renounceable rights issue aiming to raise up to $2.7 million, priced at a significant discount to its recent share value. The funds will be used to support ongoing operations, including strategic partnership efforts with C14 Consulting Group for its antiviral programs, conducting animal studies for its Hepatitis B virus compound, and maintaining and expanding its patent portfolio. The rights issue is partially underwritten by Mahe Capital, and directors plan to participate fully, highlighting confidence in the company’s strategic direction.
More about Biotron Limited
Biotron Limited is a biotechnology company focused on developing antiviral programs, with a particular emphasis on its lead clinical asset BIT225. The company is involved in the treatment of infectious diseases and aims to establish strategic partnerships to advance its portfolio.
YTD Price Performance: 390.0%
Average Trading Volume: 23,250
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $4.55M
See more insights into BIT stock on TipRanks’ Stock Analysis page.